

# **California Bioscience**

83103 Avenue 48, Ste.1B #204 Coachella, CA 92236 USA Phone : +1.6268339877 Email : info@cali-bio.com

# **Product Datasheet**

Product Name	RO-52 (SS-A) Human Recombinant
Cata No	CB500949
Source	Escherichia Coli.
Synonyms	52 kDa Ro protein, Sjoegren syndrome type A antigen, SS-A, Ro(SS-A), 52 kDa ribonucleoprotein autoantigen Ro/SS-A, Tripartite motif-containing protein 21, RING
	finger protein 81, TRIM21, RNF81, RO52, SSA1, SSA, RO-52.

# Description

TRIM21 is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The 52 kDa Ro protein is part of the RoSSA ribonucleoprotein, which includes a single polypeptide and one of four small RNA molecules. The RoSSA particle localizes to both the cytoplasm and the nucleus. Ro/SSA interacts with autoantigens in patients with Sjogren syndrome and systemic lupus erythematosus. Ribonucleoprotein particle is composed of a single polypeptide and one of four small RNA molecules. The RoSSA is present in all mammalian cells studied but has no known function. At least 2 isoforms are present in nucleated and red blood cells, and tissue specific differences in Ro/SSA proteins were identified. RO-52 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain having a molecular mass of 52kDa. The RO-52 is purified by proprietary

chromatographic techniques.

# **Physical Appearance**

Sterile Filtered clear solution.

#### Purity

Greater than 90.0% as determined by both:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

## Formulation

The protein solution contains 6M Urea, 500mM NaCl and 10mM Tris pH8.0.

#### Stability

Lyophilized RO-52 although stable at  $4^{\circ}$  for 3 weeks, should be stored desiccated below -18°C. Please prevent freeze-thaw cycles.

## Sequence

MASAARLTMMWEEVTCPICLDPFVEPVSIECGHS FCQECISQVGKGG **GSVCAVCRQRFLLKNLRPNRQLANMVNNLKEISQ** EAREGTQGERCA VHGERLHLFCEKDGKALCWVCAQSRKHRDHAM VPLEEAAQEYQEKL QVALGELRRKQELAEKLEVEIAIKRADWKKTVETQ KSRIHAEFVQQKNF LVEEEQRQLQELEKDEREQLRILGEKEAKLAQQS QALQELISELDRRC HSSALELLQEVIIVLERSESWNLKDLDITSPELRSV **CHVPGLKKMLRTC AVHITLDPDTANPWLILSEDRRQVRLGDTQQSIPG** NEERFDSYPMVLG AQHFHSGKHYWEVDVTGKEAWDLGVCRDSVRR KGHFLLSSKSGFWT IWLWNKQKYEAGTYPQTPLHLQVPPCQVGIFLDY EAGMVSFYNITDHGS LIYSFSECAFTGPLRPFFSPGFNDGGKNTAPLTLC PLNIGSQGSTDY

# \* For Non-Clinical Research Use Only \*